MedTrace Logo

Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions

NCT01750775 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2012-12-17

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of Chinese medicine Shansong Yangxin capsule for sinus bradycardia complicated with ventricular premature beats.

Conditions

  • Premature Ventricular Contraction

Interventions

DRUG

Shensong Yangxin capsule

ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks

DRUG

placebo Capsule

placebo Capsule 4 granules t.i.d. by mouth for 8 weeks

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • Third Military Medical University

    collaborator OTHER

  • kejiang Cao

    lead OTHER

Principal Investigators

  • Kejiang Cao, M.D · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-09-30
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01750775 on ClinicalTrials.gov